About ChromaCode

Leveraging a new perspective

ChromaCode is a molecular diagnostics company with a bioinformatics focus and pedigree from Illumina, Google[x], Luminex, and Caltech. We leverage patented mathematical methods and algorithmic enhancements to enrich signal processing from the most popular life science instrumentation. We are using this to extract new information on biochemistry reactions and substantially increase the performance capabilities of today’s gold-standard biochemical assays at a very low cost.

Our team is a unique mix of data scientists, molecular biologists and cloud-software developers focused on our stated Vision and Mission, which are:

Vision

Connecting all patients to the right treatment through smarter and more affordable diagnostics

Mission

We have a passion for extracting unrealized value from diagnostic information using state-of-the-art data analytics.

We use this ability to help our laboratory customers and our strategic partners:

  • Reduce healthcare costs by delivering more actionable information from existing, low-cost diagnostic tools;
  • Broaden access to cutting-edge diagnostics by empowering the large install base of widely-available molecular instruments;
  • Rapidly address new or unmet healthcare testing needs by using data science to deliver more comprehensive information and radically speed product design and development.
2011

- HDPCR™ Idea Percolated CalTech

2013

- A. Rajagopal Publishes on HDPCR

2014

- Core HDPCR patent issues

2015

- Forward Thinking Minds Converge
- Series A funding used to start ChromaCode

2016

- First prototype assay for multiplexed respiratory viruses using existing qPCR instruments

2017

- Series B funding used to move into product development

2018

- Demonstrated HDPCR on Digital PCR
- HDPCR technology launched
- Tick-borne panel launched

2011
  • HDPCR™ Idea Percolated CalTech
2013
  • A. Rajagopal Publishes on HDPCR
2014
  • Core HDPCR patent issues
2015
  • Forward Thinking Minds Converge
  • Series A funding used to start ChromaCode
2016
  • First prototype assay for multiplexed respiratory viruses using existing qPCR instruments
2017
  • Series B funding used to move into product development
2018
  • Demonstrated HDPCR on Digital PCR
  • HDPCR technology launched
  • Tick-borne panel launched

We are developing next-generation testing solutions for infectious disease, cancer and NIPT applications based on exclusive Caltech IP that leapfrogs other technologies in the midplex segment of the molecular testing market.

Market

Quantitative PCR (qPCR) is the gold standard for molecular testing with a massive installed base of instruments in clinical labs worldwide. These instruments are able to rapidly, accurately and economically identify a wide variety of molecular targets. However, in practice qPCR is limited to testing 4 or fewer different biomarkers per sample. This prevents the technology from serving the needs of physicians and clinical researchers who are increasingly demanding larger (>10 biomarker) test “panels” for infectious diseases, genetic diseases and cancer diagnostics.

These “midplex” panels represent a multibillion-dollar market segment that is growing rapidly. Current midplex instrument solutions are far from perfect.  They have a high price per test, low throughput, and require proprietary instruments. Furthermore, while ideal for high-plex applications, Next Generation Sequencing (NGS) is overkill for midplex applications and suffers from even higher costs and operational complexity.

HDPCR™ (High-Definition PCR)

ChromaCode’s HDPCR™ (High-Definition PCR) is a patented reagent and software technology that will enable the global installed base of qPCR and dPCR instruments – without modification – to deliver midplex assays at very low cost. Labs get to run midplex panels using the proven instruments, chemistries and work-flows they already use in high volume, every day, all over the world.

Products

ChromaCode’s products are comprised of per-test consumables and cloud-based data analysis software. Reagents are formulated from standard low-cost PCR chemistries such as TaqMan®. Proprietary software algorithms use digital signal processing to detect unique signatures in the data output, enabling qPCR midplex panel detection.

Business Model

We deploy our technology in three ways. First, we enable CLIA high-complexity labs by supporting development of custom applications using HDPCR™ on existing lab equipment.  Second, we sell reagent components for specific applications that can be used by labs to build their own assays.  Third, we partner with qPCR instrument and reagent manufacturers enabling them to develop, validate and commercialize multiplexed assays for the research and clinical diagnostics markets.

Market Expansion

ChromaCode has demonstrated HDPCR™ for use with digital PCR (dPCR) instruments.  We are developing high-plex digital PCR applications for liquid biopsy, non-invasive prenatal testing and others disease areas needing the high-sensitivity dPCR delivers.

Stage

We are backed by strong healthcare investors and have assembled a team of industry-leading technical and commercial staff. We will be launching our first products at the end of 2018 and invite viewers to visit our website frequently for the latest updates.